B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis

被引:16
|
作者
Moccia, Marcello [1 ,2 ]
Haider, Lukas [1 ,3 ]
Eshaghi, Arman [1 ]
van de Pavert, Steven Harry Pieter [1 ]
Morra, Vincenzo Brescia [2 ]
Patel, Amy [1 ]
Wheeler-Kingshott, Claudia Angela Michela [1 ]
Barkhof, Frederik [4 ,5 ]
Ciccarelli, Olga [1 ,6 ]
机构
[1] UCL, Dept Neuroinflammat, UCL Queen Sq Inst Neurol, Fac Brain Sci,Queen Sq MS Ctr, London, England
[2] Univ Naples Federico II, Dept Neurosci, Multiple Sclerosis Clin Care & Res Unit, Naples, Italy
[3] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria
[4] UCL, UCL Inst Healthcare Engn, Translat Imaging Grp, London, England
[5] Vrije Univ Amsterdam Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands
[6] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England
来源
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION | 2022年 / 9卷 / 01期
关键词
MENINGEAL INFLAMMATION; PATHOLOGY; THERAPY;
D O I
10.1212/NXI.0000000000001108
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and ObjectivesTo define the clinical and pathologic correlations of compartmentalized perivascular B cells in postmortem progressive multiple sclerosis (MS) brains.MethodsBrain slices were acquired from 11 people with secondary progressive (SP) MS, 5 people with primary progressive (PP) MS, and 4 controls. Brain slices were immunostained for B lymphocytes (CD20), T lymphocytes (CD3), cytotoxic T lymphocytes (CD8), neuronal neurofilaments (NF200), myelin (SMI94), macrophages/microglia (CD68 and IBA1), astrocytes (glial fibrillary acidic protein [GFAP]), and mitochondria (voltage-dependent anion channel and cytochrome c oxidase subunit 4). Differences in CD20 immunostaining intensity between disease groups and associations between CD20 immunostaining intensity and both clinical variables and other immunostaining intensities were explored with linear mixed regression models and Cox regression models, as appropriate.ResultsCD20 immunostaining intensity was higher in PPMS (Coeff = 0.410; 95% confidence interval [CI] = 0.046, 0.774; p = 0.027) and SPMS (Coeff = 0.302; 95% CI = 0.020, 0.585; p = 0.036) compared with controls. CD20 immunostaining intensity was higher in cerebellar, spinal cord, and pyramidal onset (Coeff = 0.274; 95% CI = 0.039, 0.510; p = 0.022) compared with optic neuritis and sensory onset. Higher CD20 immunostaining intensity was associated with younger age at onset (hazard ratio [HR] = 1.033; 95% CI = 1.013, 1.053; p = 0.001), SP conversion (HR = 1.056; 95% CI = 1.022, 1.091; p = 0.001), wheelchair dependence (HR = 1.472; 95% CI = 1.108, 1.954; p = 0.008), and death (HR = 1.684; 95% CI = 1.238, 2.291; p = 0.001). Higher immunostaining intensity for CD20 was associated with higher immunostaining intensity for CD3 (Coeff = 0.114; 95% CI = 0.005, 0.224; p = 0.040), CD8 (Coeff = 0.275; 95% CI = 0.200, 0.350; p < 0.001), CD68 (Coeff = 0.084; 95% CI = 0.023, 0.144; p = 0.006), GFAP (Coeff = 0.002; 95% CI = 0.001, 0.004; p = 0.030), and damaged mitochondria (Coeff = 3.902; 95% CI = 0.891, 6.914; p = 0.011).DiscussionPerivascular B cells were associated with worse clinical outcomes and CNS-compartmentalized inflammation. Our findings further support the concept of targeting compartmentalized B-cell inflammation in progressive MS.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin
    Obermeier, Birgit
    Lovato, Laura
    Mentele, Reinhard
    Brueck, Wolfgang
    Forne, Ignasi
    Imhof, Axel
    Lottspeich, Friedrich
    Turk, Katherine W.
    Willis, Simon N.
    Wekerle, Hartmut
    Hohlfeld, Reinhard
    Hafler, David A.
    O'Connor, Kevin C.
    Dornmair, Klaus
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 233 (1-2) : 245 - 248
  • [42] Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of immune Cells during CNS Autoimmunity
    Pikor, Natalia B.
    Prat, Alexandre
    Bar-Or, Amit
    Gommerman, Jennifer L.
    FRONTIERS IN IMMUNOLOGY, 2016, 6
  • [43] B cells and antibodies in multiple sclerosis
    Hemmer, Bernhard
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 28 - 28
  • [44] Characterising B cells in multiple sclerosis
    Rathbone, E.
    Durant, L.
    Douglas, M.
    Curnow, S. J.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 159 - 159
  • [45] The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies
    Racke, Michael K.
    CURRENT OPINION IN NEUROLOGY, 2008, 21 : S9 - S18
  • [46] The Role of B Cells in Multiple Sclerosis: Implications for B-Cell-Targeted Therapy
    Hirotani, M.
    Niino, M.
    Sasaki, H.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (28) : 3215 - 3222
  • [47] Targeting B cells in multiple sclerosis
    Sellebjerg, Finn
    Weber, Martin S.
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (03) : 295 - 302
  • [48] Betting on B cells in multiple sclerosis
    Link, Hans
    NATURE MEDICINE, 2008, 14 (06) : 615 - 616
  • [49] Betting on B cells in multiple sclerosis
    Hans Link
    Nature Medicine, 2008, 14 : 615 - 616
  • [50] B cell treatments for multiple sclerosis
    D. McLauchlan
    N. P. Robertson
    Journal of Neurology, 2017, 264 : 814 - 816